8 completed, 2 terminated, 1 unknown, 1 withdrawn. 12 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Completed 8, Terminated 2, Unknown 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 2, Unknown 1 |
Follow Timolol: new trials by email Literature Review of Timolol trials Research Report on Timolol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effectiveness and Safety of Timolol and Dorzolamide Loaded Contact Lenses timolol maleate and dorzolamide hydrochloride - Glaucoma | Phase 1 | Completed | University of Florida | 2 | 2018-01-18 | 2021-12-02 |
| KJ-TFC-004 Drug-drug Interaction Study [A], [B], [A]+[B](1) - Glaucoma, Eye Diseases | Phase 1 | Completed | Kukje Pharma | 32 | 2016-12-01 | 2018-04-11 |
| A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension Fixed Combination, Bimatoprost, Timolol - Open-Angle Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Completed | ForSight Vision5, Inc. | 55 | 2016-04-30 | 2019-02-25 |
| Timolol for the Treatment of Acne and Rosacea Timolol - Acne Vulgaris, Rosacea | Phase 1 | Completed | Johns Hopkins University | 8 | 2016-03-01 | 2021-11-11 |
| Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept Topical timolol maleate, placebo saline drops - Hereditary Hemorrhagic Telangiectasia | Phase 1 / Phase 2 | Completed | Unity Health Toronto | 5 | 2013-05-01 | 2023-09-21 |
| Multi-Arm Feasibility Study Evaluating OTX-TP Compared to Timolol in Treatment of Subjects With Open Angle Glaucoma OTX-TPa ~4µg/day over 2 mos. with natural tears drops, OTX-TPb ~3µg/day over 3 months with natural tears drops, Timolol Maleate (0.5%) dosed twice daily with punctum plug without drug - Glaucoma | Phase 1 | Completed | Ocular Therapeutix, Inc. | 41 | 2013-04-01 | 2016-12-12 |
| Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial) topical 0.5% Timolol maleate, Control (placebo) group - Infantile Hemangioma, Very Low Birth Weight Infants | Phase 1 | Terminated | Alice K. Gong | 26 | 2012-07-01 | 2016-11-15 |
| Treatment Study for Ischemic Optic Neuropathy With Opthalmic Timolol Maleate 0.5% Timolol maleate - Optic Neuropathy, Ischemic, Anterior Ischemic Optic Neuropathy | Phase 1 | Withdrawn | Fraser Health | 2012-06-01 | 2015-05-25 | |
| Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol Timolol, Preservative free artificial tear gel. - Sturge Weber Syndrome, Port-wine Mark | Phase 1 | Terminated | Wills Eye | 3 | 2012-02-01 | 2019-03-21 |
| Study of the Safety and Efficacy of ATS907 in Subjects With Primary Open Angle Glaucoma (POAG) and Ocular Hypertension Stage 1 - ATS907 - Dose 1, Stage 1 - ATS907 - Dose 2, Stage 1 - ATS907 - Dose 3 - Primary Open Angle Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Unknown | Altheos, Inc. | 180 | 2012-01-01 | 2012-11-01 |
| Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops Preservative free tafluprost 0.0015% eye drops, Preservative free timolol 0.5% eye drops, Preservative free FDC of tafluprost 0.0015% and timolol 0.5% eye drops - Healthy Volunteers | Phase 1 | Completed | Santen Oy | 15 | 2011-09-01 | 2012-06-08 |
| Interaction Study of Timolol Eye Drops and Paroxetine Capsules Paroxetine, Placebo, timolol maleate - Healthy | Phase 1 | Completed | Santen Oy | 12 | 2009-04-01 | 2010-01-28 |
Glaucoma (3) · Ocular Hypertension (3) · Glaucoma, Open-Angle (2) · Acne Vulgaris (1) · Eye Diseases (1) · Hemangioma, Capillary (1) · Ischemia (1) · Optic Nerve Diseases (1) · Optic Neuropathy, Ischemic (1) · Premature Birth (1) · Rosacea (1) · Sturge-Weber Syndrome (1) · Telangiectasia, Hereditary Hemorrhagic (1) · Vascular Malformations (1)
Santen Oy (2) · Alice K. Gong (1) · Altheos, Inc. (1) · ForSight Vision5, Inc. (1) · Fraser Health (1) · Johns Hopkins University (1) · Kukje Pharma (1) · Ocular Therapeutix, Inc. (1) · Unity Health Toronto (1) · University of Florida (1) · Wills Eye (1)
United States (5) · Canada (2) · Finland (2) · Panama (1) · South Africa (1) · South Korea (1)
Alex V Levin, MD, MHSc (1) · Alice K Gong, M.D. (1) · Alice K Gong, MD (1) · Barbara Wirostko, MD (1) · Janne Backman, MD, PhD (1) · Kyung-sang Yu, Ph.d., M.B.A (1) · Luis A Garza, MD, PhD (1) · Marie E Faughnan, MD MSc FRCPC (1) · Mark Sherwood (1) · Martin A SuttonBrown, MD (1) · Michelle Chen, PhD (1)
U54NS065705 (1)